Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 21 studies | 45% ± 13% | |
lung | 16 studies | 45% ± 19% | |
intestine | 11 studies | 28% ± 10% | |
kidney | 8 studies | 36% ± 17% | |
uterus | 6 studies | 28% ± 8% | |
liver | 5 studies | 25% ± 6% | |
lymph node | 5 studies | 49% ± 21% | |
brain | 4 studies | 56% ± 27% | |
bone marrow | 4 studies | 39% ± 19% | |
breast | 4 studies | 27% ± 9% | |
adipose | 3 studies | 29% ± 11% | |
adrenal gland | 3 studies | 28% ± 8% | |
thymus | 3 studies | 31% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 99% | 20474.59 | 456 / 459 | 94% | 2099.25 | 1050 / 1118 |
lung | 100% | 52810.48 | 578 / 578 | 91% | 2940.12 | 1048 / 1155 |
kidney | 100% | 14335.03 | 89 / 89 | 89% | 2797.46 | 805 / 901 |
thymus | 90% | 10133.99 | 589 / 653 | 86% | 1871.87 | 519 / 605 |
uterus | 88% | 7776.15 | 149 / 170 | 78% | 1873.64 | 360 / 459 |
prostate | 89% | 7905.29 | 219 / 245 | 73% | 802.43 | 367 / 502 |
intestine | 84% | 13697.11 | 814 / 966 | 71% | 1328.21 | 374 / 527 |
bladder | 81% | 6979.43 | 17 / 21 | 67% | 1349.04 | 336 / 504 |
esophagus | 78% | 5795.36 | 1129 / 1445 | 68% | 935.27 | 125 / 183 |
skin | 70% | 7055.26 | 1263 / 1809 | 75% | 2252.77 | 356 / 472 |
stomach | 65% | 6338.32 | 235 / 359 | 77% | 1521.35 | 220 / 286 |
adrenal gland | 92% | 15648.29 | 238 / 258 | 46% | 406.01 | 105 / 230 |
ovary | 34% | 2132.67 | 62 / 180 | 86% | 1957.53 | 371 / 430 |
pancreas | 18% | 1208.93 | 59 / 328 | 89% | 1978.67 | 159 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 11122.03 | 29 / 29 |
spleen | 100% | 58638.02 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 99% | 23270.54 | 1197 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 54169.34 | 912 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 91% | 14178.65 | 1220 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 2566.34 | 41 / 45 |
brain | 29% | 2906.74 | 772 / 2642 | 59% | 1247.25 | 413 / 705 |
liver | 25% | 1421.31 | 56 / 226 | 51% | 699.73 | 209 / 406 |
heart | 52% | 3176.90 | 452 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 29% | 434.61 | 23 / 80 |
muscle | 23% | 1176.12 | 186 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0050870 | Biological process | positive regulation of T cell activation |
GO_0002469 | Biological process | myeloid dendritic cell antigen processing and presentation |
GO_0043382 | Biological process | positive regulation of memory T cell differentiation |
GO_2000516 | Biological process | positive regulation of CD4-positive, alpha-beta T cell activation |
GO_0032831 | Biological process | positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation |
GO_0002503 | Biological process | peptide antigen assembly with MHC class II protein complex |
GO_0001916 | Biological process | positive regulation of T cell mediated cytotoxicity |
GO_0045622 | Biological process | regulation of T-helper cell differentiation |
GO_0006955 | Biological process | immune response |
GO_0002250 | Biological process | adaptive immune response |
GO_0002491 | Biological process | antigen processing and presentation of endogenous peptide antigen via MHC class II |
GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
GO_0050890 | Biological process | cognition |
GO_0050778 | Biological process | positive regulation of immune response |
GO_0002504 | Biological process | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II |
GO_0001772 | Cellular component | immunological synapse |
GO_0031902 | Cellular component | late endosome membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0120281 | Cellular component | autolysosome membrane |
GO_0030666 | Cellular component | endocytic vesicle membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0005764 | Cellular component | lysosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
GO_0032588 | Cellular component | trans-Golgi network membrane |
GO_0009986 | Cellular component | cell surface |
GO_0000139 | Cellular component | Golgi membrane |
GO_0098553 | Cellular component | lumenal side of endoplasmic reticulum membrane |
GO_0042613 | Cellular component | MHC class II protein complex |
GO_0012507 | Cellular component | ER to Golgi transport vesicle membrane |
GO_0030658 | Cellular component | transport vesicle membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0042608 | Molecular function | T cell receptor binding |
GO_0030247 | Molecular function | polysaccharide binding |
GO_0023026 | Molecular function | MHC class II protein complex binding |
GO_0032395 | Molecular function | MHC class II receptor activity |
GO_0005515 | Molecular function | protein binding |
GO_0042605 | Molecular function | peptide antigen binding |
Gene name | HLA-DRA |
Protein name | HLA class II histocompatibility antigen, DR alpha chain (MHC class II antigen DRA) MHC class II antigen HLA class II histocompatibility antigen, DR alpha chain (MHC cell surface glycoprotein) (Major histocompatibility complex, class II, DR alpha) HLA-DRA protein HLA class II histocompatibility antigen, DR alpha chain HLA-DRA HLA-DRA (MHC class II antigen) |
Synonyms | HLA-DRA1 |
Description | FUNCTION: An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells . Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes . In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins . Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance . The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides . The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules . . |
Accessions | A1A436 ENST00000395388.7 ENST00000415767.2 ENST00000411524.6 ENST00000613328 ENST00000416883.6 ENST00000383259.6 ENST00000427753.2 ENST00000411505.2 A0A0G2JMH6 ENST00000442960.6 ENST00000613328.1 ENST00000383258.3 Q30125 P01903 A1A435 A0A0G2JH46 B0UXD8 ENST00000383127.6 Q30118 ENST00000374982.5 ENST00000418111.2 ENST00000414698.6 A0A1V0E3V4 ENST00000434866.2 |